Greater Cannabis Company Valuation

Is GCAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GCAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GCAN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GCAN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GCAN?

Key metric: As GCAN is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GCAN. This is calculated by dividing GCAN's market cap by their current book value.
What is GCAN's PB Ratio?
PB Ratio	-0.4x
Book	-US$806.04k
Market Cap	US$362.09k

GCAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-4.7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does GCAN's PB Ratio compare to its peers?

The above table shows the PB ratio for GCAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.9x
TTNP Titan Pharmaceuticals	0.9x	n/a	US$3.5m
KDCE Kid Castle Educational	0.1x	n/a	US$357.2k
ACAN AmeriCann	0.09x	n/a	US$465.9k
EYEN Eyenovia	2.4x	37.7%	US$9.0m
GCAN Greater Cannabis Company	n/a	n/a	US$362.1k

Price-To-Book vs Peers: GCAN has negative equity and a Price-To-Book Ratio (-0.4x) compared to the peer average (0.9x).

Price to Book Ratio vs Industry

How does GCAN's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 Companies	Price / Book	Estimated Growth	Market Cap
SHWZ Medicine Man Technologies	0.09x	n/a	US$8.02m
TNFA TNF Pharmaceuticals	0.2x	n/a	US$3.20m
UPC Universe Pharmaceuticals	0.1x	n/a	US$2.71m
CLVR Clever Leaves Holdings	0.07x	n/a	US$1.75m

24 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: GCAN has negative equity and a Price-To-Book Ratio (-0.4x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is GCAN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GCAN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GCAN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

8.2%

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.5%

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

-0.2%

-7.1%